Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis Baass

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Atherosclerosis|September 9, 2020
Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experienceSumayah Aljenedil, Latifah Alothman, Alexandre M Bélanger, et al.
Journal of the Endocrine Society|January 30, 2020
Molecular Characterization of Familial Hypercholesterolemia in a North American CohortAbhimanyu Garg, Sergio Fazio, P Barton Duell, et al.
The New England Journal of Medicine|September 3, 2024
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis RiskGerald F Watts, Robert S Rosenson, Robert A Hegele, et al.
The Journal of Biological Chemistry|December 22, 2016
The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIADelia Susan-Resiga, Emmanuelle Girard, Robert Scott Kiss, et al.
Clinical Genetics|July 5, 2022
Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE geneBritt E Heidemann, Charlotte Koopal, Alexis Baass, et al.
Tropical Medicine & International Health : TM & IH|October 27, 2021
Hepatic steatosis is associated with anthropometry, cardio-metabolic disease risk, sex, age and urbanisation, but not with ethnicity in adult KenyansSophie E Kastberg, Helene S Lund, Emanuella De Lucia-Rolfe, et al.
Journal of Clinical Lipidology|July 26, 2025
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participantsAsia Sikora Kessler, T Michelle Brown, Emily Bratlee-Whitaker, et al.
The Canadian Journal of Cardiology|November 14, 2021
Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH RegistryGabrielle Roy, Patrick Couture, Jacques Genest, et al.
American Journal of Preventive Cardiology|June 15, 2026
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR TrialsChristie M Ballantyne, Alexis Baass, Robert S Rosenson, et al.
Atherosclerosis|October 2, 2018
Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registryLiam R Brunham, Isabelle Ruel, Etienne Khoury, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Atherosclerosis|September 9, 2020
Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experienceSumayah Aljenedil, Latifah Alothman, Alexandre M Bélanger, et al.
Journal of the Endocrine Society|January 30, 2020
Molecular Characterization of Familial Hypercholesterolemia in a North American CohortAbhimanyu Garg, Sergio Fazio, P Barton Duell, et al.
The New England Journal of Medicine|September 3, 2024
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis RiskGerald F Watts, Robert S Rosenson, Robert A Hegele, et al.
The Journal of Biological Chemistry|December 22, 2016
The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIADelia Susan-Resiga, Emmanuelle Girard, Robert Scott Kiss, et al.
Clinical Genetics|July 5, 2022
Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE geneBritt E Heidemann, Charlotte Koopal, Alexis Baass, et al.
Tropical Medicine & International Health : TM & IH|October 27, 2021
Hepatic steatosis is associated with anthropometry, cardio-metabolic disease risk, sex, age and urbanisation, but not with ethnicity in adult KenyansSophie E Kastberg, Helene S Lund, Emanuella De Lucia-Rolfe, et al.
Journal of Clinical Lipidology|July 26, 2025
Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participantsAsia Sikora Kessler, T Michelle Brown, Emily Bratlee-Whitaker, et al.
The Canadian Journal of Cardiology|November 14, 2021
Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH RegistryGabrielle Roy, Patrick Couture, Jacques Genest, et al.
American Journal of Preventive Cardiology|June 15, 2026
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR TrialsChristie M Ballantyne, Alexis Baass, Robert S Rosenson, et al.
Atherosclerosis|October 2, 2018
Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registryLiam R Brunham, Isabelle Ruel, Etienne Khoury, et al.
Pageof 10